Andreessen Horowitz embraces ‘weak AI,’ diagnostics and cell circuits at launch of $750M fund

With its third life sciences fund in four years, hybrid investment firm Andreessen Horowitz is looking to invest its $750 million Bio Fund III in multidisciplinary therapeutic, diagnostic and healthcare delivery companies whose approach to product development is more rooted in engineering than discovery.

Vijay Pande told BioCentury that designing technologies, instead of uncovering new biology or compounds, allows companies to take a longer view. “That approach allows you to be thinking down the line, all the way through payers.”...